ABSTRACT
Purpose: This study aims at determining the amount of mercury released over time from amalgam after treatment in healthy subjects and to examine the relation of mercury with serum MT-1 and SOD-1 levels. Materials and methods: Amalgam filling was applied to the 15 subjects aged 19-22 years and blood samples were collected before treatment and 1 day, 7 days, 21 days and 35 days after treatment. Mercury analysis of serum samples was performed using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). In addition, MT-1 and SOD-1 levels in serum samples were measured using commercial enzyme-linked immunosorbent assay (ELISA). Friedman test and Spearman's correlation analysis was performed to analyse the data. p value was interpreted in significance level of 0.05. Results: As a result of the analysis for MT-1, it was found that the values decreased over time and this decrease was statistically significant after 21 days (p<0.05). In addition, it was found that SOD-1 decreased over time, but this decrease was not statistically significant . In terms of released mercury, there was no statistically significant difference among the values of mercury released over time . According to the results of correlation analysis, no statistically significant relationship was found among the variables. Conclusion: The results of the present study indicated that the amount of mercury released from the tested amalgam were found to be tolerable and no significant relationship was found between MT-1 and SOD-1.
ABSTRACT
BACKGROUND: Cisplatin is a non-specific platinum-based (derivative) chemotherapeutic agent that causes an increase in free radicals activity in the liver. Antioxidant activity of taxifolin has been demonstrated previously, and it has been reported that taxifolin inhibits the hydroxyl, radical in experimental studies. OBJECTIVES: No studies were found in the current literature examining the protective effect of taxifolin on cisplatin-induced oxidative liver damage. We aimed to determine the protective effect of taxifolin on cisplatin-induced hepatotoxicity in an experimental study. MATERIAL AND METHODS: In total, 18 albino Wistar male rats were assigned into 3 groups: healthy controls (HC group), 5 mg/kg of cisplatin administered for 8 days (CIS group) and 50 mg/kg of taxifolin + 5 mg/kg of cisplatin administered for 8 days (TCG group). Malondialdehyde (MDA), total glutathione (tGSH), total oxidant (TOS), and total antioxidant (TAS) capacity levels were measured in the extracted liver tissue. RESULTS: Liver tissue MDA and TOS levels were significantly higher in the CIS group. In contrast, tGSH and TAS levels were significantly lower in the CIS group, administered cisplatin alone (p < 0.001), compared to other groups. In the TCG group, administered cisplatin + taxifolin, MDA and TOS levels were significantly lower, whereas tGSH and TAS levels were significantly higher than in the CIS group (p < 0.001). CONCLUSIONS: These results suggest that taxifolin may be useful in preventing cisplatin-related liver injury.
